Pathalys Pharma Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $105M

  • Investors
  • 12

Pathalys Pharma General Information

Description

Developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseases. The company creates upacicalcet, which is a novel calcimimetic with the potential to improve the treatment of SHPT (secondary hyperparathyroidism) in hemodialysis patients by mimicking the action of calcium on tissues through the activation of the calcium-sensing receptor that is expressed in various human organ tissues, enabling healthcare companies to treat patients with end-stage critical kidney disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4000 Center at North Hills
  • Suite 470
  • Raleigh, NC 27609
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 4000 Center at North Hills
  • Suite 470
  • Raleigh, NC 27609
  • United States

Pathalys Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pathalys Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 07-Aug-2024 $105M Completed Clinical Trials - Phase 3
2. Early Stage VC 13-Jan-2023 Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 01-Mar-2022 $11M $11M Completed Clinical Trials - General
To view Pathalys Pharma’s complete valuation and funding history, request access »

Pathalys Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-2
Series A-1 3,090,996 $0.000100 $9.71 $9.71 1x $9.71 11.37%
To view Pathalys Pharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Pathalys Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseas
Drug Discovery
Raleigh, NC
8 As of 2024

Chicago, IL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pathalys Pharma Competitors (1)

One of Pathalys Pharma’s competitors is Oxalo Therapeutics, a Accelerator/Incubator Backed company based in Chicago, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxalo Therapeutics Accelerator/Incubator Backed Chicago, IL
You’re viewing 1 of 1 competitors. Get the full list »

Pathalys Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pathalys Pharma Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Japan Post Bank Asset Management PE/Buyout Minority
JPMorgan Life Sciences Private Capital Venture Capital Minority
KB Investment Venture Capital Minority
Marshall Wace Hedge Fund Minority
Samsara BioCapital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Pathalys Pharma FAQs

  • When was Pathalys Pharma founded?

    Pathalys Pharma was founded in 2021.

  • Where is Pathalys Pharma headquartered?

    Pathalys Pharma is headquartered in Raleigh, NC.

  • What is the size of Pathalys Pharma?

    Pathalys Pharma has 8 total employees.

  • What industry is Pathalys Pharma in?

    Pathalys Pharma’s primary industry is Drug Discovery.

  • Is Pathalys Pharma a private or public company?

    Pathalys Pharma is a Private company.

  • What is the current valuation of Pathalys Pharma?

    The current valuation of Pathalys Pharma is .

  • What is Pathalys Pharma’s current revenue?

    The current revenue for Pathalys Pharma is .

  • How much funding has Pathalys Pharma raised over time?

    Pathalys Pharma has raised $266M.

  • Who are Pathalys Pharma’s investors?

    Japan Post Bank Asset Management, JPMorgan Life Sciences Private Capital, KB Investment, Marshall Wace, and Samsara BioCapital are 5 of 12 investors who have invested in Pathalys Pharma.

  • Who are Pathalys Pharma’s competitors?

    Oxalo Therapeutics is a competitor of Pathalys Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process